Nothing Special   »   [go: up one dir, main page]

CU20150140A7 - Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituídas - Google Patents

Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituídas

Info

Publication number
CU20150140A7
CU20150140A7 CUP2015000140A CU20150140A CU20150140A7 CU 20150140 A7 CU20150140 A7 CU 20150140A7 CU P2015000140 A CUP2015000140 A CU P2015000140A CU 20150140 A CU20150140 A CU 20150140A CU 20150140 A7 CU20150140 A7 CU 20150140A7
Authority
CU
Cuba
Prior art keywords
dihydroimidazo
composition
kinazolins
substituted
inhibitor
Prior art date
Application number
CUP2015000140A
Other languages
English (en)
Other versions
CU24400B1 (es
Inventor
Dr Ningshu Liu
Katja Haike
Juliane Paul
Dr Antje Margret Wengner
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU20150140A7 publication Critical patent/CU20150140A7/es
Publication of CU24400B1 publication Critical patent/CU24400B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a una composición que comprende una combinación de: a) un compuesto del tipo de las 2,3-dihidroimidazo [1,2-c]quinazolinas de fórmula general I en donde los significados de R1, R2 y R3 son los que se definen en las reivindicaciones y b)un agente activo adicional que se seleciona del grupo que consiste en el inhibidor selectivo de la PI3K GS-1101, el inhibidor de las BTK ibrutinib, el compuesto inhibidor de las IKK BAY B y el refametinib (BAY 86-9766, RDEA-119).
CU2015000140A 2013-04-08 2014-04-04 Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas CU24400B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13162710 2013-04-08
EP13184240 2013-09-13
PCT/EP2014/056768 WO2014166820A1 (en) 2013-04-08 2014-04-04 Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas

Publications (2)

Publication Number Publication Date
CU20150140A7 true CU20150140A7 (es) 2016-10-28
CU24400B1 CU24400B1 (es) 2019-04-04

Family

ID=50439383

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2015000140A CU24400B1 (es) 2013-04-08 2014-04-04 Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas

Country Status (28)

Country Link
US (2) US9999623B2 (es)
EP (1) EP2983669B1 (es)
JP (1) JP6368353B2 (es)
KR (1) KR102304108B1 (es)
CN (1) CN105263497B (es)
AP (1) AP2015008750A0 (es)
AU (1) AU2014253348B2 (es)
BR (1) BR112015025304B1 (es)
CA (1) CA2908776C (es)
CL (1) CL2015002978A1 (es)
CR (1) CR20150523A (es)
CU (1) CU24400B1 (es)
DO (1) DOP2015000256A (es)
EA (2) EA037577B1 (es)
ES (1) ES2708350T3 (es)
HK (1) HK1220121A1 (es)
IL (1) IL241543B (es)
JO (1) JOP20140141B1 (es)
MX (1) MX2015014171A (es)
MY (1) MY192626A (es)
NI (1) NI201500148A (es)
PE (1) PE20151780A1 (es)
PH (1) PH12015502317A1 (es)
SG (2) SG10201710539QA (es)
TN (1) TN2015000452A1 (es)
TW (2) TWI675663B (es)
UA (2) UA122822C2 (es)
WO (1) WO2014166820A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
WO2015082376A2 (en) * 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Use of pi3k-inhibitors
US10124007B2 (en) 2013-12-03 2018-11-13 Bayer Pharma Aktiengesellschaft Combination of PI3K-inhibitors
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
WO2016087488A1 (en) * 2014-12-03 2016-06-09 Bayer Pharma Aktiengesellschaft Administration regime for aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives
WO2016087490A1 (en) * 2014-12-03 2016-06-09 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
CN107864625B (zh) 2015-03-09 2021-05-28 拜耳制药股份公司 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
PT3954690T (pt) 2015-07-02 2023-06-06 Acerta Pharma Bv Formas sólidas e formulações de (s)-4-(8-amino-3-(1-(but- 2-inoil)pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n- (piridin-2-il)benzamida
EP3411497A1 (en) * 2016-02-01 2018-12-12 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
SG10202007322PA (en) * 2016-02-01 2020-09-29 Bayer Pharma AG Copanlisib biomarkers
CN108884098B (zh) 2016-03-08 2021-09-14 拜耳制药股份公司 2-氨基-N-[7-甲氧基-2,3-二氢咪唑并[1,2-c]喹唑啉-5-基]嘧啶-5-甲酰胺类
EP3219329A1 (en) * 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
US10689378B2 (en) * 2016-06-20 2020-06-23 Novartis Ag Triazolopyridine compounds and uses thereof
US10676479B2 (en) * 2016-06-20 2020-06-09 Novartis Ag Imidazolepyridine compounds and uses thereof
WO2018054782A1 (en) * 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
CN109937041B (zh) * 2017-05-18 2022-04-12 江苏恒瑞医药股份有限公司 一种ezh2抑制剂与btk抑制剂联合在制备治疗肿瘤的药物中的用途
US11185549B2 (en) 2017-06-28 2021-11-30 Bayer Consumer Care Ag Combination of a PI3K-inhibitor with an androgen receptor antagonist
RU2745397C1 (ru) 2017-09-13 2021-03-24 Гуандун Оппо Мобайл Телекоммьюникейшнз Корп., Лтд. Способ, терминальное устройство и сетевое устройство обработки данных
TW201922256A (zh) 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
CA3157789A1 (en) * 2019-10-15 2021-04-22 Bayer Aktiengesellschaft 2-methyl-aza-quinazolines
JP7440360B2 (ja) 2020-06-30 2024-02-28 東日本旅客鉄道株式会社 山形鋼材の研磨装置
CN115120596A (zh) * 2021-03-26 2022-09-30 上海璎黎药业有限公司 一种喹唑啉化合物及药物组合物的应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1400959A (en) 1919-04-26 1921-12-20 Ste Chim Usines Rhone Process and apparatus for carrying out chemical reactions by catalysis
US1364099A (en) 1919-09-10 1921-01-04 Flannery Bolt Co Staybolt structure for boilers
US1400975A (en) 1920-10-11 1921-12-20 Page Henry Benjiman Dirigible headlight for motor-vehicles
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
JP2003277383A (ja) * 2002-03-14 2003-10-02 Bayer Ag 光学活性ピリジン誘導体およびそれを含む医薬
ES2367141T3 (es) 2002-09-30 2011-10-28 Bayer Pharma Aktiengesellschaft Derivados de azol-pirimidina condensados.
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
WO2009091550A2 (en) 2008-01-14 2009-07-23 Bayer Healthcare Llc Sulfone substituted 2,3-dihydroimidazo [1,2-c] quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
CN102958540B (zh) 2010-04-16 2015-09-02 拜耳知识产权有限责任公司 含取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合
CA2797398C (en) 2010-05-14 2017-01-24 Lg Electronics Inc. Method for allocating resources in a wireless communication system and a device for the same
UA113280C2 (xx) * 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
JP5790016B2 (ja) 2011-02-18 2015-10-07 コベルコ建機株式会社 ハイブリッド建設機械
CA2820709C (en) * 2011-02-28 2016-02-16 Sunshine Lake Pharma Co., Ltd. Substituted quinoline compounds and methods of use
WO2012121953A1 (en) * 2011-03-08 2012-09-13 The Trustees Of Columbia University In The City Of New York Methods and pharmaceutical compositions for treating lymphoid malignancy
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
CA2840687C (en) * 2011-07-01 2020-04-28 Dana-Farber Cancer Institute, Inc. Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma
US20150141470A1 (en) * 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
US8993891B2 (en) 2012-06-28 2015-03-31 Thomas & Betts International, Inc. Lift and pivot grommet
JP6499657B2 (ja) 2013-12-03 2019-04-10 バイエル ファーマ アクチエンゲゼルシャフト Ｐｉ３ｋ阻害剤の組み合わせ
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
CN107864625B (zh) 2015-03-09 2021-05-28 拜耳制药股份公司 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品
BR112017019190A2 (pt) 2015-03-09 2018-04-24 Bayer Healthcare Pharmaceuticals Inc uso de 2,3-di-hidroimidazo[1,2-c]quinazolinas substituídas

Also Published As

Publication number Publication date
TN2015000452A1 (en) 2017-04-06
BR112015025304B1 (pt) 2022-09-27
PH12015502317A1 (en) 2016-02-10
ES2708350T3 (es) 2019-04-09
CR20150523A (es) 2016-01-29
EP2983669B1 (en) 2018-10-24
EA201591932A1 (ru) 2016-04-29
TW201517909A (zh) 2015-05-16
TWI675663B (zh) 2019-11-01
WO2014166820A1 (en) 2014-10-16
AU2014253348B2 (en) 2019-05-23
SG11201507265XA (en) 2015-10-29
US20180193349A1 (en) 2018-07-12
US10226469B2 (en) 2019-03-12
JP2016515601A (ja) 2016-05-30
AP2015008750A0 (en) 2015-09-30
AU2014253348A1 (en) 2015-10-08
BR112015025304A2 (pt) 2017-07-18
EP2983669A1 (en) 2016-02-17
KR20150138858A (ko) 2015-12-10
MY192626A (en) 2022-08-29
US9999623B2 (en) 2018-06-19
KR102304108B1 (ko) 2021-09-23
TWI689307B (zh) 2020-04-01
EA201792650A1 (ru) 2018-04-30
EA037577B1 (ru) 2021-04-16
DOP2015000256A (es) 2015-12-31
EA031493B1 (ru) 2019-01-31
JP6368353B2 (ja) 2018-08-01
SG10201710539QA (en) 2018-01-30
TW201924690A (zh) 2019-07-01
JOP20140141B1 (ar) 2021-08-17
PE20151780A1 (es) 2015-12-20
US20160058770A1 (en) 2016-03-03
CU24400B1 (es) 2019-04-04
NZ712033A (en) 2021-03-26
CA2908776A1 (en) 2014-10-16
UA119537C2 (uk) 2019-07-10
CN105263497B (zh) 2019-04-30
UA122822C2 (uk) 2021-01-06
IL241543B (en) 2019-08-29
HK1220121A1 (zh) 2017-04-28
CA2908776C (en) 2021-08-10
NI201500148A (es) 2015-11-30
EA031493B9 (ru) 2019-12-18
CN105263497A (zh) 2016-01-20
MX2015014171A (es) 2015-12-16
CL2015002978A1 (es) 2016-04-15

Similar Documents

Publication Publication Date Title
CU20150140A7 (es) Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituídas
CR20160076A (es) NUEVOS DERIVADOS DE TRIAZOLO[4,5-d]PIRIMIDINA
DOP2016000208A (es) Benzimidazol-2-aminas como inhibidores de midh1
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
CR20150447A (es) Nuevos derivados de pirazol
DOP2015000305A (es) Inhibidores de bromodominios
ECSP15030799A (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y métodos de tratamiento con los mismos
AR091604A1 (es) Potenciacion de autofagia o aumento de longevidad por administracion de urolitinas o precursores de las mismas, compuesto
CR20180072A (es) Nuevos compuestos biciclicos como inhibidores de atx
CO7350620A2 (es) Nuevos derivados de piridina
UY35395A (es) Inhibidores de bromodominios tetracíclicos
MA38982A1 (fr) Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
DOP2015000077A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
ECSP14013231A (es) Imidazopiridazinas sustituidas con amino
CR20150440A (es) Nuevos derivados de piridina
DOP2011000260A (es) Pirimidinas fusionadas
CR20150204A (es) Nuevos derivados de piridina
CR20150511A (es) Nuevos derivados de purina
CR20150555A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina
CR20150210A (es) Nuevos derivados de pirazina como agonistas receptores de cb2
CL2017001100A1 (es) Nuevas triazolo[4,5-d]pirimidinas
DOP2016000007A (es) Pirazolpiridinas sustituidas
UY35332A (es) Derivados de pirrolotriazina como inhibidores de pi3k
DOP2016000268A (es) Compuestos de azol amido–sustituidos como inhibidores de tnks1 y/o tnks2